CVRX
CVRx, Inc. NASDAQ Listed Jun 30, 2021$5.15
Pre-mkt
$5.29
+2.72%
Mkt Cap $134.3M
52w Low $4.74
6.8% of range
52w High $10.81
50d MA $6.30
200d MA $7.70
P/E (TTM)
—
EV/EBITDA
—
P/B
3.4x
Debt/Equity
1.3x
ROE
-135.6%
P/FCF
-3.3x
RSI (14)
44.40
ATR (14)
$0.36
Beta
1.12
50d MA
$6.30
200d MA
$7.70
Avg Volume
366.8K
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
9201 West Broadway Avenue · Minneapolis, MN 55445 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | -0.42 | -0.46 | -9.5% | 5.69 | -1.6% | -13.0% | -4.2% | +2.3% | +8.9% | +15.7% | — |
| Nov 5, 2025 | AMC | -0.50 | -0.49 | +2.0% | 9.79 | +8.6% | +2.7% | -3.4% | -0.4% | +1.8% | -3.3% | — |
| Aug 4, 2025 | AMC | -0.52 | -0.57 | -9.6% | 7.55 | -1.7% | -9.8% | +3.7% | -1.7% | +4.3% | +3.7% | — |
| May 8, 2025 | AMC | -0.56 | -0.53 | +5.4% | 7.78 | -23.3% | -38.7% | -0.4% | +14.5% | -2.8% | +17.0% | — |
| Feb 4, 2025 | AMC | -0.37 | -0.43 | -16.2% | 16.25 | -1.1% | -7.2% | -2.5% | -0.5% | +1.7% | -2.1% | — |
| Oct 29, 2024 | AMC | -0.45 | -0.57 | -26.7% | 10.74 | -1.0% | +31.0% | -6.8% | +2.1% | +12.3% | +2.5% | — |
| Jul 29, 2024 | AMC | -0.51 | -0.65 | -27.5% | 9.27 | -2.6% | -14.5% | +7.8% | -2.9% | -0.8% | +2.8% | — |
| Apr 30, 2024 | AMC | -0.53 | -1.04 | -96.2% | 15.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% | — |
| Jan 25, 2024 | AMC | -0.55 | -0.44 | +20.0% | 29.20 | -0.3% | -6.7% | -1.6% | -3.2% | -3.1% | -0.5% | — |
| Oct 26, 2023 | AMC | -0.57 | -0.43 | +24.6% | 12.84 | +15.7% | +2.4% | -1.9% | +3.7% | +1.7% | +0.1% | — |
| Jul 25, 2023 | AMC | -0.57 | -0.56 | +1.8% | 16.94 | +4.5% | +5.4% | -4.2% | +3.8% | +1.0% | +3.0% | — |
| Apr 27, 2023 | AMC | -0.57 | -0.55 | +3.5% | 9.48 | +7.5% | +22.8% | +9.5% | -1.2% | -0.5% | +0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.81 | $7.93 | +1.5% | -1.2% | -3.1% | -1.6% | +0.0% | -1.6% |
| Feb 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.69 | $5.60 | -1.6% | -13.0% | -4.2% | +2.3% | +8.9% | +15.7% |
| Nov 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.79 | $10.63 | +8.6% | +2.7% | -3.4% | -0.4% | +1.8% | -3.3% |
| Nov 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.79 | $10.63 | +8.6% | +2.7% | -3.4% | -0.4% | +1.8% | -3.3% |
| Aug 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.55 | $7.42 | -1.7% | -9.8% | +3.7% | -1.7% | +4.3% | +3.7% |
| May 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.78 | $5.97 | -23.3% | -38.7% | -0.4% | +14.5% | -2.8% | +17.0% |
| May 9 | JP Morgan | Downgrade | Neutral → Underweight | — | $7.78 | $5.97 | -23.3% | -38.7% | -0.4% | +14.5% | -2.8% | +17.0% |
| Apr 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.54 | $8.00 | -30.7% | -46.3% | +17.3% | -10.9% | -3.9% | +4.8% |
| Apr 8 | Lake Street | Maintains | Buy → Buy | — | $11.54 | $8.00 | -30.7% | -46.3% | +17.3% | -10.9% | -3.9% | +4.8% |
| Feb 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $16.25 | $16.07 | -1.1% | -7.2% | -2.5% | -0.5% | +1.7% | -2.1% |
| Feb 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.25 | $16.07 | -1.1% | -7.2% | -2.5% | -0.5% | +1.7% | -2.1% |
| Jan 17 | Craig-Hallum | Maintains | Buy → Buy | — | $17.30 | $17.42 | +0.7% | +1.8% | +4.4% | -6.5% | +5.3% | -2.0% |
| Jan 14 | William Blair | Upgrade | Market Perform → Outperform | — | $15.04 | $16.02 | +6.5% | +7.4% | +5.3% | +1.8% | +1.8% | +4.4% |
| Dec 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.48 | $14.17 | +5.1% | +1.2% | -0.3% | +0.1% | -1.5% | -4.3% |
| Nov 4 | Craig-Hallum | Maintains | Buy → Buy | — | $13.40 | $15.02 | +12.1% | +12.3% | +2.5% | +0.0% | +0.6% | +0.0% |
| Oct 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.74 | $10.63 | -1.0% | +31.0% | -6.8% | +2.1% | +12.3% | +2.5% |
| Oct 30 | Lake Street | Maintains | Buy → Buy | — | $10.74 | $10.63 | -1.0% | +31.0% | -6.8% | +2.1% | +12.3% | +2.5% |
| Oct 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.74 | $10.63 | -1.0% | +31.0% | -6.8% | +2.1% | +12.3% | +2.5% |
| Oct 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.15 | $10.11 | -0.4% | +0.2% | -0.6% | -0.4% | +2.2% | +4.4% |
| Aug 26 | Lake Street | Maintains | Buy → Buy | — | $8.73 | $8.76 | +0.3% | +14.5% | -2.6% | +2.0% | -0.7% | +0.0% |
| Jul 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.27 | $9.03 | -2.6% | -14.5% | +7.8% | -2.9% | -0.8% | +2.8% |
| Jul 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.27 | $9.03 | -2.6% | -14.5% | +7.8% | -2.9% | -0.8% | +2.8% |
| Jul 11 | Craig-Hallum | Maintains | Buy → Buy | — | $7.15 | $7.29 | +2.0% | +19.0% | +14.2% | -0.5% | +2.5% | -2.0% |
| Jul 11 | Lake Street | Maintains | Buy → Buy | — | $7.15 | $7.29 | +2.0% | +19.0% | +14.2% | -0.5% | +2.5% | -2.0% |
| May 1 | William Blair | Downgrade | Outperform → Market Perform | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| May 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| May 1 | JP Morgan | Downgrade | Overweight → Neutral | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| May 1 | Lake Street | Maintains | Buy → Buy | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| May 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| Jan 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.20 | $29.10 | -0.3% | -6.7% | -1.6% | -3.2% | -3.1% | -0.5% |
| Jan 26 | JP Morgan | Maintains | Overweight → Overweight | — | $29.20 | $29.10 | -0.3% | -6.7% | -1.6% | -3.2% | -3.1% | -0.5% |
| Dec 27 | Lake Street | Maintains | Buy → Buy | — | $31.04 | $31.44 | +1.3% | -0.9% | +7.3% | -4.8% | -3.0% | -3.1% |
| Dec 20 | JP Morgan | Maintains | Overweight → Overweight | — | $23.63 | $23.51 | -0.5% | +0.9% | +6.2% | -1.3% | +24.2% | -0.9% |
| May 3 | Lake Street | Maintains | Buy → Buy | — | $12.60 | $12.88 | +2.2% | -0.5% | +0.9% | -0.3% | -2.6% | -1.9% |
| Feb 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.45 | $17.69 | +1.4% | -1.8% | +0.8% | -0.2% | +1.5% | +0.1% |
| Feb 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $18.00 | $18.51 | +2.8% | +1.9% | -9.0% | +4.5% | -1.8% | +0.8% |
| Jan 27 | JP Morgan | Maintains | Overweight → Overweight | — | $14.37 | $15.54 | +8.1% | +2.9% | -1.4% | +4.3% | +9.4% | +11.2% |
| Nov 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.24 | $11.00 | +7.4% | +1.1% | +16.3% | +1.7% | +2.6% | -5.4% |
No insider trades available.
8-K · 5.02
!!! Very High
CVRx, Inc. -- 8-K 5.02: Executive Change
Jun 9
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CVRX's gross margin expansion to 87% signals improving operational efficiency and pricing power, while modest expense growth suggests disciplined cost management that should drive profitability gains.
Apr 13
8-K · 5.02
!!! Very High
CVRx, Inc. -- 8-K 5.02: Executive Change
CVRx granted performance stock units to executive officers to enhance retention and align incentives with near-term strategic objectives, potentially strengthening leadership stability.
Mar 3
8-K
CVRx, Inc. -- 8-K Filing
CVRx reported fourth quarter and full year 2025 financial results, with newly appointed CFO Jared Oasheim overseeing the neuromodulation medical device company's ongoing commercialization efforts.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 4,024,861 | $38M | — | Mar 2026 |
| 2 | Gsk Plc | 1,007,583 | $10M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 911,310 | $9M | New | Mar 2026 |
| 4 | Royal Bank Of Canada | 706,950 | $7M | Added | Mar 2026 |
| 5 | Morgan Stanley | 761,282 | $5M | Reduced | Dec 2025 |
| 6 | Tudor Investment Corp | 197,340 | $2M | New | Mar 2026 |
| 7 | Jane Street Group, Llc | 225,349 | $2M | Added | Dec 2025 |
| 8 | Northern Trust Corp | 150,123 | $1M | Added | Mar 2026 |
| 9 | Quantinno Capital Management Lp | 115,818 | $1M | Added | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 114,167 | $1M | Added | Mar 2026 |
| 11 | Ubs Group Ag | 103,810 | $982K | Added | Mar 2026 |
| 12 | Bnp Paribas Financial Markets | 98,670 | $933K | Added | Mar 2026 |
| 13 | Vanguard Portfolio Management Llc | 94,849 | $897K | New | Mar 2026 |
| 14 | Aqr Capital Management Llc | 89,904 | $850K | New | Mar 2026 |
| 15 | Cresset Asset Management, Llc | 71,802 | $579K | Added | Sep 2025 |
| 16 | Nuveen, Llc | 42,749 | $404K | Added | Mar 2026 |
| 17 | Rbf Capital, Llc | 40,000 | $378K | — | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 38,542 | $365K | Added | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 30,969 | $293K | Reduced | Mar 2026 |
| 20 | Citadel Advisors Llc | 26,627 | $252K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$134.3M
Enterprise Value
$108.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.15x
P/B
3.42x
P/S
2.27x
P/FCF
-3.30x
EV/EBITDA
—
Shares Out
26.1M
Financials (TTM)
Revenue
$59.1M
Net Income
-$52.7M
EBITDA
-$46.0M
Free Cash Flow
-$40.8M
Op Cash Flow
-$40.2M
EPS Basic
$-2.04
EPS Diluted
$-2.02
EPS Forward
$-1.98
Gross Margin
85.5%
Op Margin
-84.6%
Net Margin
-89.1%
Balance Sheet
Total Assets
$104.8M
Total Liab.
$65.5M
Total Equity
$39.3M
Cash
$75.7M
LT Debt
$50.2M
Book Value/Sh
$1.51
Debt/Equity
1.29x
Current Ratio
7.63
Quick Ratio
6.72
Returns & Growth
ROE
-135.6%
ROA
-50.9%
ROIC
-56.0%
Rev Growth YoY
+10.4%
EPS Growth YoY
+23.0%
Price Returns
2W
-2.8%
1M
-25.7%
3M
-31.6%
6M
-43.1%
12M
-16.0%
Technicals
52W High
$10.81
52W Low
$4.74
50d MA
$6.30
200d MA
$7.70
RSI (14)
44.40
ATR (14)
$0.36
Beta
1.12
Avg Volume
367K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.50
High
$13.00
Low
$10.00
Median
$11.50
Data updated apr 25, 2026 4:10am
· Source: financialmodelingprep.com